The Good Bug (TGB), a gut health startup, has raised ₹100 crore in a Series B funding round led by Susquehanna Asia VC, the VC arm of Susquehanna International Group. The round also saw participation from existing investors, including Fireside Ventures.
The fresh funds raised will be used for R&D, to expand its footprint across India, and to accelerate innovation in gut microbiome science for chronic health conditions, including obesity and women’s wellness.
Previously in 2024, The Good Bug raised $4 million (₹35 crore) in its Series A extension round led by Sharrp Ventures, the family office of Marico Group Chairman Harsh Mariwala. TGB had earlier secured its Series A funding in 2023 from Fireside Ventures.
The latest fundraise brings its total funding to around $20 million.
Founded in 2022 by Keshav Biyani and Prabhu Karthikeyan, The Good Bug offers science-backed probiotics in the form of oro-soluble powders for adults and kids aiming to improve overall core health, gut health, and daily wellness. It also provide prebiotic fibres, detox shots, ferments, and others.
The Good Bug recently launched the Advanced Metabolic System, offering a sustainable and science-backed approach to weight loss. The Good Bug’s clinically tested solution naturally elevates GLP-1 levels, reduces chronic gut inflammation, and effectively regulates appetite, leading to lasting weight and health improvements.
Keshav Biyani, Co-founder of The Good Bug, said, “This partnership with Susquehanna Asia VC, combined with the continued support from Fireside Ventures and others, is a powerful endorsement of our mission to transform health outcomes through gut bacterial science. This new capital infusion will be pivotal in accelerating our research and development efforts, driving ground breaking innovations in gut health through rigorous R&D. Additionally, we will bolster our marketing and distribution strategies to enhance consumer awareness and expand our reach across India. Attracting top-tier talent across research, technology, science, and business will further strengthen our foundation. We are energized by this momentum and committed to unlocking scalable, science-driven solutions that improve health outcomes for millions.”
Bhavani Rana, Investment Advisor to Susquehanna Asia VC, said, “We are thrilled to invest in The Good Bug, a brand that is redefining the digestive wellness space. Their holistic approach, rooted in gut microbiome science, emphasizes the importance of digestive wellness as the foundation for overall well-being—a vision that resonates deeply with the growing awareness of its role in preventing many health issues. What sets TGB apart is the strength of its leadership team and their exceptional ability to execute on their vision. With strong momentum and a clear strategy, the company is well-positioned to capitalize on the macro tailwinds of India’s rapidly expanding nutraceuticals market. We look forward to supporting TGB’s growth as they continue to lead in key categories and expand into new areas, building a strong, consumer-focused brand in the evolving wellness landscape.”
Ankur Khaitan, Principal at Fireside Ventures, said, “We are delighted to deepen our support for The Good Bug. We’ve witnessed firsthand the impact of their customer-first approach and purpose-led innovation. Our belief in their vision and leadership has only grown stronger, and we look forward to strengthening this long-term partnership as they scale a category-defining brand.”
